Tevogen Inc TVGN

$6.53 -0.28 (-4.11%)

Valuation

Market cap
42,520,000
Revenue TTM
$0
Net income TTM
$-26,280,000
PE ratio
0.00
Forward PE
—
Profit margin
0.00%
Debt to equity
-0.72

Trading

Volume
39,400
Avg volume
7,766
Day's range
$6.35 – $6.81
Shares out
6,511,000
Stochastic %K
23%
Beta
0.19
Analysts
Strong Buy
Price target
$100.00

Price

Company profile

Tevogen Inc., a clinical-stage specialty immunotherapy company, develops off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and other disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment of ambulatory high-risk adult COVID-19 patients; and in Phase 1 clinical trial to treat acute SARS-CoV-2 patients with B-cell cancer immune s...

Show more

Tevogen Inc., a clinical-stage specialty immunotherapy company, develops off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and other disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment of ambulatory high-risk adult COVID-19 patients; and in Phase 1 clinical trial to treat acute SARS-CoV-2 patients with B-cell cancer immune suppression, and other B cell immune suppressed acute SARS-CoV-2 patients with a B cell cancer indication, as well as Long COVID prevention and treatment. It is also developing TVGN 920, a preclinical trial drug for treating cervical cancer; TVGN 960, a preclinical trial drug for treating oropharyngeal cancer; TVGN 601, a preclinical trial drug for treating multiple sclerosis; TVGN 930, a preclinical trial drug for treating Epstein-Barr virus associated lymphomas; and TVGN 116, a product candidate targeted at hepatitis B. It also offers artificial intelligence platform for drug development. Tevogen Inc. was formerly known as Tevogen Bio Holdings Inc. and changed its name to Tevogen Inc. in July 2026. The company was incorporated in 2020 and is headquartered in Warren, New Jersey.

Industry
Biotechnology
Sector
Healthcare
Phone
877 838 6436
Website
https://tevogen.com
Address
15 Independence Boulevard, Suite #210, Warren, United States

Latest news

Stocktwits

LewisIntegrated Oct 23, 5:27 PM
If you’ve ever wanted to catch a short squeeze early instead of watching it rip after the fact, this group is built for that. Sharing momentum, setups, and what we’re watching as it develops, not when it’s already gone. Click link and join for Free ⭐ $PW $NVNO $TVGN !!
0 replies
NGCS Oct 8, 9:10 PM
$TVGN because using algos someone is controlling price in order to get our shares cheaper. This is going to explode in few weeks. Something very strong is brewing. NFA. Best regards.
1 replies
theSnip3r Oct 8, 6:13 PM
$TVGN why down
0 replies
NGCS Oct 1, 7:11 PM
$TVGN https://es.tradingview.com/news/tradingview:9023c195a54e0:0-tevogen-regains-nasdaq-global-market-compliance-after-meeting-50m-market-value-requirement/
0 replies
NGCS Sep 30, 10:49 PM
$TVGN OFFICIAL: NASDAQ COMPLIANCE FULLY SECURED! Fresh 8-K filed! Nasdaq sent official written confirmation (Sept 29) that $TVGN has regained full compliance with the $50M Market Value requirement (Rule 5450(b)(2)(A)). All compliance matters with Nasdaq are now OFFICIALLY CLOSED. No delisting risk. Float locked, balance sheet clean, reg issues solved. Next stop: Pending MSO/CRO definitive 8-K. $TVGN #Biotech #Bullish #Nasdaq
0 replies
NGCS Sep 18, 12:04 PM
$TVGN Valuation Model based on Revenue Mix (MSO/CRO + Tevogen.AI Licences) 🧬🤖 Today there are only 6,4 million shares (float 3,5M - 4,2M shares). But even Assuming worst case fully diluted ~21M OS (including CEO 8M sh ONLY if $1B revenue milestones from last SEC filing on 16th sept): 🔹 Base Case ($250M Rev): $180M MSO + $70M AI = ~$65 - $70 / sh 🔹 Bull Case ($600M Rev): $400M MSO + $200M AI = ~$170 - $180 / sh 🔹 TechBio Mega Case ($1B Rev): $500M MSO + $500M AI = ~$360 - $380 / sh AI SaaS multiples (10x-15x) completely dwarf traditional CRO valuation. High margins = massive repricing. 📈 NFA - Do your own DD
0 replies
NGCS Sep 11, 7:09 AM
$TVGN https://www.investing.com/news/sec-filings/tevogen-regains-nasdaq-compliance-with-minimum-market-value-requirement-93CH-4896349
0 replies
NGCS Sep 11, 6:59 AM
$TVGN New SEC 8-K confirms $TVGN received formal written notice from NASDAQ: Minimum Market Value Compliance HAS BEEN MET and the matter is officially CLOSED. The regulatory overhang is gone. Now all eyes turn to the final catalyst: The MSO/CRO Definitive Agreement (PR/8-K) • Float: ~3.5M–4.2M (Extremely tight) • Short Interest: 68.5k shares with a ~13.4 Days to Cover! • Order Book: Completely empty on the Ask—a single spark clears the board. The stage is set for the M&A launch. IMO Short squeeze could happen in any moment. #TVGN #LowFloat #ShortSqueeze #Biotech #SEC #NASDAQ
0 replies